Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug abrocitinib tested in everyday use

NCT ID NCT05250115

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the drug abrocitinib works for adults with moderate to severe atopic dermatitis (eczema) in real-world clinics in Germany. Researchers tracked 112 participants for up to 12 months to see if their skin cleared or improved. The goal was to understand the drug's effectiveness and safety outside of controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
abrocitinib
What this could lead to
If successful, this study could confirm that abrocitinib is a safe and effective treatment option for managing moderate to severe atopic dermatitis in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. The study was terminated early, which may limit the data collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

112 people

The number who actually took part.

Started

May 2022

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A prospective, single-arm, multi-center, observational non-interventional study looking at adult patients with moderate-severe atopic dermatitis, who have been chosen to start treatment with Abrocitinib in Germany according to the current routine practice of the treating physician.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥18 years * Confirmed diagnosis of AD by dermatologist prior to study inclusion * Patient for whom the decision to initiate treatment with abrocitinib was made as part of routine clinical practice irrespective of the patients being 1. abrocitinib naive or, 2. patients who reinitialize treatment with abrocitinib after being off treatment for ≥28 days prior to study inclusion * Patient is eligible for abrocitinib treatment according to Summary of Product Characteristics (SmPC) * Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the non-interventional study Exclusion Criteria: * Contraindications according to SmPC * Receipt of any investigational drug within 3 months or longer if required according to wash-out period prior to inclusion or participation in a clinical trial during observation period * Patients being treated with abrocitinib within a time period of \<28 days prior to the timepoint of study inclusion * Patients who are investigational site staff members or patients who are Pfizer employees directly involved in the conduct of the non-interventional study * Patients who are unable to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis, atopic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis, atopic

Contacts and locations

Locations

  • "Magdeburger company for Medical studies & Services"

    Magdeburg, Saxony-Anhalt, 39104, Germany

  • BAG Freitag und Knöll

    Falkensee, 14612, Germany

  • Cutaneum Praxis Dr. Buck

    Hamburg, 20095, Germany

  • Dermatologie Bad Kreuznach - Dr. med. Georg Mauer

    Bad Kreuznach, 55543, Germany

  • Dermatologie Mölln, Praxis Dr Segert

    Mölln, 23879, Germany

  • Dermatologische Gemeinschaftspraxis Dres. Quist PartG

    Mainz, Rhineland-Palatinate, 55128, Germany

  • Dermatologische Praxis im Hautzentrum Johannis Dr. med. Esther Völkel

    Nuremberg, 90419, Germany

  • Dermatologische Spezialpraxis Dr. med. Ralph von Kiedrowski

    Selters, 56242, Germany

  • Dermatologisches Studienzentrum Hunsrück - DSH

    Simmern, 55469, Germany

  • Dr. Beate Schwarz

    Langenau, 89129, Germany

  • Dr. Christiane Handrick Hautarztpraxis

    Berlin, 10117, Germany

  • Dres. Ziethen-Stavermann GbR

    Berlin, 12353, Germany

  • Elbe Kliniken Stade - Buxtehude GmbH

    Buxtehude, Lower Saxony, 21614, Germany

  • Haut- und Laserzentrum Freisung Prof. Kurzen

    Freising, 85354, Germany

  • Hautarztpraxis Dorittke / Kardorff

    Mönchengladbach, 41236, Germany

  • Hautarztpraxis Dr. Brinkmann, Schult & Samimi-Fard

    Gladbeck, 45964, Germany

  • Hautarztpraxis Dr. Hoffmann

    Witten, 58453, Germany

  • Hautarztpraxis Dr. Susanne Gißler-Walter

    Mutterstadt, 67112, Germany

  • Hautarztpraxis Dr. Virgil Mihaescu

    Augsburg, 86150, Germany

  • Hautarztpraxis Dr. med Michael Loth

    Gernsbach, 76593, Germany

  • Hautarztpraxis Dr. med. Daniela Kasche

    Buxtehude, 21614, Germany

  • Hautarztpraxis Dr. med. Matthias Lütten

    Hamburg, 20095, Germany

  • Hautarztpraxis Dr. med. Thomas Schirmer

    Berlin, 12489, Germany

  • Hautarztpraxis Mortazawi

    Remscheid, 42897, Germany

  • Hautarztpraxis Weid

    Bingen, 55411, Germany

  • Hautarztpraxis an der Hase Studienzentrum

    Bramsche, 49565, Germany

  • Hautzentrum

    Bergen, 18528, Germany

  • Hautzentrum Weißensee

    Berlin, 13086, Germany

  • Hautärzte Braunschweig

    Braunschweig, 38114, Germany

  • Hautärztliche Gemeinschaftspraxis

    Ahaus, 48688, Germany

  • Kosmedikulm

    Kulmbach, 95326, Germany

  • Praxis Dr. A. Magerl

    Bensheim, 64625, Germany

  • Praxis Dr. Quack

    München, 81539, Germany

  • Praxis Dr. Voth

    Cologne, 50677, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, 20246, Germany

  • ZENTderma, Dr. Rolf Ostendorf

    Mönchengladbach, 41061, Germany

  • dermaSANA

    Karlsruhe, 76131, Germany

  • ÜUeberoertliche Gemeinschaftspraxis Jost Kai Rietkoetter Robert Jablonka

    Gelsenkirchen, North Rhine-Westphalia, 32423, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.